Spera Pharma made a debut exhibit at CPhI worldwide 2017, which was held for three days from October 24, 2017 in Frankfurt, Germany. Details of the Spera Pharma business model and technologies were actively presented to the many attendees coming from companies in European countries, and it was felt that there was a great responsiveness globally to the potential of our CMC technology.
The exhibition featured “Discover The #1 CDMO in Japan” as the headline message, and focused on strengthening the position of Spera Pharma as a Bushu Pharmaceutical Group company that wishes to expand business globally. The aim was to accelerate this by disseminating knowledge of our technical strengths to overseas.
At the exhibition booth we eagerly exchanged information and had some detailed business meetings, incorporating a slideshow to introduce our technologies and facilities as well as short presentations by researchers. The attendees especially took an interest in our Japanese company for product quality and its wealth of CMC R&D experience. The exhibition was a first step to develop business globally for Spera Pharma, which was only started in July 2017 and is virtually unknown globally.
Five researchers went to Frankfurt and communicated with the attendees face to face. On the way home, the researchers remarked that they further felt the importance of CMC technologies in drug R&D and the diverse technical needs. One researcher commented that he realized the high degree of confidence that is placed in Japanese technical quality. But additionally, the hurdle for R&D technologies becomes higher and he wants to provide more advanced R&D technology cultivated from his experience in Takeda Pharmaceuticals.
We greatly appreciated all the visits to our booth and will do our best to respond to all of the requests and opinions received.